Statement
12 Jan 2023
Statement to the IHR Review Committee on amendments to the International Health Regulations
IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.
Read more
Infographic
5 Dec 2022
Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.
Read more
External study
21 Sep 2022
The role of intellectual property in the biopharmaceutical sector
To better understand this resulting dichotomy, this white paper answers five key questions, with a focus on applications related to innovation in the life sciences sector and the COVID-19 pandemic.
Read more